CD44 and OTP are strong prognostic markers for pulmonary carcinoids

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 2197-2207

  Swarts, Dorian R A ^a   Henfling, Mieke E R ^a   Van Neste, Leander ^f   Van Suylen, Robert Jan ^c   Dingemans, Anne Marie C ^b   Dinjens, Winand N M ^d   Haesevoets, Annick ^a   Rudelius, Martina ^g   Thunnissen, Erik ^e   Volante, Marco ^h   Van Criekinge, Wim ⁱ   Van Engeland, Manon ^a   Ramaekers, Frans C S ^a   Speel, Ernst Jan M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MDxHealth   (Belgium)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h SAN LUIGI GONZAGA HOSPITAL   (Italy)

ⁱ GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA; ORTHOPEDIA HOMEOBOX PROTEIN; REARRANGED DURING TRANSFECTION PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD44 GENE; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MUTATIONAL ANALYSIS; ONCOGENE; ONSET AGE; ORTHOPEDIA HOMEOBOX GENE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PULMONARY CARCINOID; REAL TIME POLYMERASE CHAIN REACTION; REARRANGED DURING TRANSFECTION GENE; SURVIVAL TIME; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOID TUMOR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE TISSUE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877089334     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3078     Document Type: Article

References (47)

1. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities. Biochim Biophys Acta 2012;1826:255-71.
2. Beasley MB, Thunnissen FB, Hasleton PhS, Barbareschi M, Pugatch B, Geisinger K, et al. Carcinoid tumour. In:Travis WD, Brambilla E, Muller-Harmelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004. p.59-62
3. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii65-71.
4. Granberg D, Eriksson B, Wilander E, Grimfjard P, Fjallskog ML, Oberg K, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-91. (Pubitemid 33100242)
5. Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005;103:509-15.
6. Görtz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999;154:429-36. (Pubitemid 29094093)
7. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-65.
8. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70-76. (Pubitemid 46630496)
9. Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007;31:192-97. (Pubitemid 46150082)
10. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52. (Pubitemid 26415213)
11. Granberg D, Wilander E, Oberg K, Skogseid B. Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors. Int J Cancer 1999;84:484-88.
12. Lim E, Goldstraw P, Nicholson AG, Travis WD, Jett JR, Ferolla P, et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008;3:1194-201.
13. Rugge M, Fassan M, Clemente R, Rizzardi G, Giacomelli L, Pennelli G, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008;14:149- 54.
14. Swarts DR, Claessen SM, Jonkers YM, van Suylen RJ, Dingemans AM, de Herder WW, et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol 2011;179:1129-37.
15. Van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 2003;63:3133-37. (Pubitemid 36735864)
16. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS ONE 2009;4:e7012.
17. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367-75. (Pubitemid 40637828)
18. de Krijger RR, Petri BJ, van Nederveen FH, Korpershoek E, de Herder WW, De Muinck Keizer-Schrama SM, et al. Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci 2006;1073:166-76. (Pubitemid 44912009)
19. Luo Y, Tsuchiya KD, Il PD, Fausel R, Kanngurn S, Welcsh P, et al. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 2012 Jul 2. [Epub ahead of print].
20. Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers 2011;26:50-57.
21. Coppola D, Clarke M, Landreneau R, Weyant RJ, Cooper D, Yousem SA. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol 1996;9:484-90. (Pubitemid 26171662)
22. Nguyen VN, Mirejovsky T, Melinova L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000;47:400-08.
23. Sun X, Gong Y, Talamonti MS, Rao MS. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in carcinoid tumors. Mod Pathol 2002;15:1333-38. (Pubitemid 35463002)
24. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
25. Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997;90:2217-33. (Pubitemid 27392706)
26. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011;121:1064-74.
27. Bohm JP, Niskanen LK, Pirinen RT, Kiraly K, Kellokoski JK, Moisio KI, et al. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. J Pathol 2000;192:321-27.
28. Favrot MC, Combaret V, Lasset C. CD44 - a new prognostic marker for neuroblastoma. N Engl J Med 1993;329:1965. (Pubitemid 24003130)
29. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-49. (Pubitemid 27098007)
30. Kaufmann M, Heider KH, Sinn HP, von MG, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-19.
31. Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-72. (Pubitemid 24351702)
32. Takanami I, Takeuchi K, Naruke M. Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma. Oncol Rep 2000;7:1065-67.
33. Acampora D, Postiglione MP, Avantaggiato V, Di BM, Vaccarino FM, Michaud J, et al. Progressive impairment of developing neuroendocrine cell lineages in the hypothalamus of mice lacking the Orthopedia gene. Genes Dev 1999;13:2787-800.
34. Amir-Zilberstein L, Blechman J, Sztainberg Y, Norton WH, Reuveny A, Borodovsky N, et al. Homeodomain protein otp and activity-dependent splicing modulate neuronal adaptation to stress. Neuron 2012;73:279-91.
35. Wang W, Lufkin T. The murine Otp homeobox gene plays an essential role in the specification of neuronal cell lineages in the developing hypothalamus. Dev Biol 2000;227:432-49.
36. Kim MS, Lee J, Oh T, Moon Y, Chang E, Seo KS, et al. Genome-wide identification of OTP gene as a novel methylation marker of breast cancer. Oncol Rep 2012;27:1681-88.
37. Lee CH, Chang HK, Lee HW, Shin DH, Roh MS. The interobserver variability for diagnosing pulmonary carcinoid tumor. Korean J Pathol 2010;44:267-71.
38. Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 2008;3:1410-15.
39. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998;29:272-79. (Pubitemid 28123925)
40. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005;29:179-87. (Pubitemid 40170635)
41. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996;81:2041-46. (Pubitemid 26175924)
42. Futami H, Egawa S, Tsukada T, Maruyama K, Bandoh S, Noguchi M, et al. A novel somatic point mutation of the RET Proto-oncogene in tumor tissues of small cell lung cancer patients. Jpn J Cancer Res 1995;86:1127-30.
43. Futami H, Egawa S, Takasaki K, Tsukada T, Shiraishi M, Yamaguchi K. Allelic loss of DNA locus of the RET proto-oncogene in small cell lung cancer. Cancer Lett 2003;195:59-65. (Pubitemid 36588979)
44. Mulligan LM, Timmer T, Ivanchuk SM, Campling BG, Young LC, Rabbitts PH, et al. Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma. Gene Chromosome Cancer 1998;21:326-32. (Pubitemid 28165040)
45. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-45.
46. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-77.
47. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.